Moderna Shares Hit Multi-Year High Ahead of Melanoma Vaccine Data

What happened

Moderna has become one of the most dramatic biotech comebacks of this market cycle. On Friday, October 9, the mRNA developer rose more than 9% in early trading to a new 52-week high of $216.95, then gave back part of the move and traded around $208.69.36 Separately, Moderna was reported reaching $212.53 earlier in the session, with a market value near $82 billion.6 By late morning on the Nasdaq, Yahoo Finance quoted the stock at $207.65, up 5.4%, and showed a year-to-date return above 600%.31

The immediate trigger was technical. Before the open on October 9, Moderna formally joined the Nasdaq-100, taking the place of Warner Bros. Discovery. Nasdaq had announced the change on October 1.30 Funds that track the index are required to own its members, so the change created automatic demand. More than 200 investment products with over $800 billion in assets follow the benchmark.36 One analysis said this mechanical buying "did the heavy lifting" on the day and revealed more about index mechanics than about the business.

The index addition was the spark, but the scientific story built the rally. Over the past year, Moderna's shares climbed from a low near $22 to above $200.2936

The science behind the rerating

The rally rests on intismeran autogene, an individualized mRNA cancer therapy that Moderna is developing with Merck. In August, the two companies said the treatment, given with Merck's Keytruda, met its primary endpoint in the Phase 3 INTerpath-001 trial. The trial enrolled melanoma patients whose tumors had already been surgically removed.2632 One deep-dive analysis reported that the study enrolled 1,137 high-risk patients and also met its key secondary endpoint, distant metastasis-free survival.34 The announcement repriced Moderna almost overnight, lifting its market value from about $25 billion toward $70 billion. Merck shares gained about 12.6% the same day.26

This matters for biotech beyond one ticker. A positive randomized Phase 3 trial of a personalized neoantigen vaccine is a first for the field. Bank of America analyst Alec Stranahan called it a watershed that lets Moderna diversify beyond infectious disease and could ease its capital pressures.28 Moderna's leadership has described oncology as the next planned step for a platform first proven in simpler vaccines. Management also told a healthcare forum that it sees Moderna as a broad mRNA company spanning vaccines, oncology and rare diseases.23

The rest of the business has improved too. The FDA approved mFLUSIVA on August 5, making it the first mRNA flu vaccine cleared in the U.S. It is authorized for adults 50 and older and is Moderna's fifth approved product.34 Coverage also points to a flu-COVID combination shot in Europe, which suggests steadier seasonal demand rather than revenue that depends on pandemic waves.27

Where the coverage agrees, and where it splits

Almost every outlet agrees on the timeline and the main catalysts: the index entry on October 9, the August Phase 3 result, and full data due October 24 in an ESMO Presidential Symposium slot in Madrid.34 They also agree that Wall Street's price targets sit far below the stock price. MarketScreener showed a Hold consensus from 23 analysts with an average target of $119.56.29 Other trackers put the mean near $116.84, $120.67 or about $121.2726 Whichever figure you use, the consensus is roughly $90 or more below where the stock traded on Friday.

The figures themselves vary. Reported year-to-date gains range from about 537% to 545% to 594% to more than 604%.352831 Reported 52-week highs also vary, from $212.22 to $216.95, depending on source and timing.3036 These gaps mainly reflect a stock that moves several percent a day, but they show how fast the story has changed.

The real split is over valuation. Bulls point to the size of the opportunity: one estimate puts peak sales for intismeran in high-risk melanoma at about $5 billion.25 Skeptics point to the current numbers. Moderna's second-quarter revenue was $145 million, up only about 2% from a year earlier.2930 Another report described a quarterly net loss of roughly $782 million and R&D spending of $651 million. GuruFocus put the price-to-sales ratio above 34, against a historical median near 8.4. Its own fair-value model put intrinsic value at less than $24 a share.24

Citigroup's Geoff Meacham cut the stock to Sell while raising his target from $60 to $80, arguing that the price had run ahead of near-term commercial prospects.2636 Morgan Stanley raised its target to $95 and kept an Equal-Weight rating.36 Insiders have not bought shares in the past year and have sold $64.6 million worth.24

Reading the rally

My view is that Friday's high marks a peak in flows and attention more than new information about the drug. The index buying is a one-time event. Once tracking funds have filled their positions, that demand goes away while the stock sits close to its record. One analyst flagged exactly this risk.34 Moderna's swings on unchanged clinical news support that view. The stock rose 8% on October 5 because investors expected the Madrid data, not because of anything new.22 It fell 6% to 7% after announcing a new chief operating officer, Juan Andres, and the retirement of technical operations chief Jerh Collins.2327

In effect, the stock has been valued on a one-sentence topline result. The hazard ratios and survival curves are still unpublished.34 One analyst laid out the October 24 test: a recurrence-free survival hazard ratio below 0.65 with a benefit on distant metastasis would count as strong, while anything above 0.8 would be a warning sign.34 Some outlets also listed earlier long-term results for the intismeran–Keytruda combination in resected high-risk melanoma, including five-year data showing a sustained recurrence-free survival benefit. That record adds some confidence that the Phase 3 effect is real.33 Still, after a run this large, a good result may be priced in already, while a mixed one would leave little support underneath the shares.

The balance sheet cushions the risk to the company, though not to the stock price. Moderna ended June with about $6.9 billion in cash and investments and expects $4.7 billion to $5.2 billion at year-end.34 A disappointing data day would not threaten solvency, but it could quickly reverse the rerating.

The sector backdrop

Moderna is rising while biotech broadly is losing momentum. The XBI biotech index nearly reached $170 in August, more than double its level a year earlier. It has since slipped on disappointing trial readouts, higher interest rates, worries about the midterm elections and fewer acquisitions of public companies.20 Cantor Fitzgerald said the XBI had traded sideways for months. A Raymond James survey found investors "more cautious," and some now see a drop as more likely than a rebound.20 The XBI is still up about 24% for the year.2 A BofA note said biotech had beaten the S&P 500 by about 11 percentage points through late September.5

Other biotech stocks are also making new highs on specific catalysts rather than sector strength. Vir Biotechnology hit a 52-week high of $11.96 after more than doubling over the past year, helped by a payment from its Astellas partnership and progress in prostate cancer and hepatitis delta.8 AbbVie reached a 52-week high after receiving two FDA Breakthrough Therapy designations for its antibody-drug conjugate ABBV-400.7 Kodiak Sciences rose after a positive Phase 3 result in wet AMD. CareDx gained after Medicare coverage of its transplant tests4 and reached its highest level in more than four years.17 By contrast, Legend Biotech posted strong five-year CAR-T durability data and revenue growth of about 52%, yet its stock remains about half its 52-week high.1

The pattern is clear. Investors are paying for confirmed clinical and regulatory wins while the broader index stalls. Moderna is the most extreme example: a stock now valued at more than $80 billion based largely on one trial result.31 Peer comparisons suggest the market is rewarding this specific drug, not mRNA in general. BioNTech, which has a personalized cancer vaccine at an earlier stage, is roughly flat for the year.3532

What to watch

The key date is October 24, when Moderna and Merck present the full INTerpath-001 data at ESMO and hold an investor webcast. Third-quarter earnings follow on November 5.31 Until then, Moderna's new high mostly measures investor expectations. The Madrid data will show whether those expectations hold up.